Get the Stockscreener App
1.10
1.85%
0.02
After Hours:
1.12
0.02
+1.82%
Rallybio Corp stock is traded at $1.10, with a volume of 68,813.
It is up +1.85% in the last 24 hours and up +6.80% over the past month.
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
See More
Previous Close:
$1.08
Open:
$1.1
24h Volume:
68,813
Relative Volume:
1.06
Market Cap:
$45.22M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-0.5636
EPS:
-1.9516
Net Cash Flow:
$-60.27M
1W Performance:
+10.65%
1M Performance:
+6.80%
6M Performance:
-29.49%
1Y Performance:
-52.17%
1-Day Range:
$1.0553
$1.12
1-Week Range:
$0.9803
$1.1487
52-Week Range:
$0.95
$3.46
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
1.10 | 45.22M | 0 | -74.56M | -60.27M | -1.9516 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Flat on Release of New Findings - Baystreet.ca
Rallybio advances Phase 2 trial for rare pregnancy condition - Investing.com
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Marketscreener.com
Rallybio CEO to Present at Evercore ISI HealthCONx Conference in December | RLYB Stock News - StockTitan
Rallybio's SWOT analysis: rare disease biotech stock advances FNAIT treatment - Investing.com
Rallybio to Host Key Webcast on RLYB116 C5 Inhibitor Development Updates | RLYB Stock News - StockTitan
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women - MSN
Rallybio Launches Phase 2 Trial for Groundbreaking Pregnancy Treatment RLYB212 | RLYB Stock News - StockTitan
Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India
FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World
Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal
Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace
Rallybio Narrows Losses 37%, Advances RLYB212 Trial with $75M Cash Runway | RLYB Stock News - StockTitan
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice
Two former Alexion leaders fight through a tough market to sustain a rare disease biotech - BioPharma Dive
Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada
Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada
Rallybio advances novel FNAIT prevention trial - Investing.com India
Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa
Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks
Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire
Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia
Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com
Rallybio shares hold Buy rating on HPP treatment data - Investing.com India
Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan
Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia
Rallybio reveals higher FNAIT risk across populations - Investing.com
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire
Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Rallybio announces board member resignation - Investing.com
Rallybio announces board member resignation By Investing.com - Investing.com UK
Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks
Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com
RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire
Rallybio - FiercePharma
Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):